These results suggest that the basal level of Nrf2 and/or its downstream gene expression and/or genes expressed under ARE may serve as a biomarker for predicting therapeutic response of cancers to RRx-001 treatment, and for selection and stratification of cancer patients who would be most likely to respond and benefit from RRx-001 therapy. Here, NFE2L2 is linked to cancer.